Overall and progression-free survival with everolimus, temsirolimus, or sorafenib as second targeted therapies for metastatic renal cell carcinoma: A retrospective US chart review.

被引：0
|
作者：
Yang, Hongbo
Wong, Michael K. K.
Signorovitch, James E.
Wang, Xufang
Liu, Zhimei
Liu, Nathan S.
Qi, Zhengyun
George, Daniel J.
机构：
[1] Anal Grp Inc, Boston, MA USA
[2] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA
[3] Novartis Pharmaceut, Florham Pk, NJ USA
[4] Novartis Pharmaceut, E Hanover, NJ USA
[5] Duke Univ, Med Ctr, Durham, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4612
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Effect of Concomitant pH-Elevating Medications with Pazopanib on Progression-Free Survival and Overall Survival in Patients with Metastatic Renal Cell Carcinoma
    McAlister, Renee K.
    Aston, Jonathan
    Pollack, Megan
    Du, Liping
    Koyama, Tatsuki
    Chism, David D.
    [J]. ONCOLOGIST, 2018, 23 (06): : 686 - 692
  • [32] Real-world effectiveness, dosing, and drug costs of everolimus (EVE) and axitinib (AXI) as second targeted therapies (TTs) for advanced renal cell carcinoma (aRCC) in the US: a retrospective chart review
    Jonasch, Eric
    Pal, Sumanta K.
    Signorovitch, James E.
    Li, Nanxin
    Liu, Zhimei
    Perez, Jose Ricardo
    Vogelzang, Nicholas J.
    [J]. BJU INTERNATIONAL, 2015, 116 : 13 - 13
  • [33] A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapy
    Kim, Sung Han
    Kim, Sohee
    Joo, Jungnam
    Seo, Ho Kyung
    Joung, Jae Young
    Lee, Kang Hyun
    Chung, Jinsoo
    [J]. BMC CANCER, 2016, 16
  • [34] A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapy
    Sung Han Kim
    Sohee Kim
    Jungnam Joo
    Ho Kyung Seo
    Jae Young Joung
    Kang Hyun Lee
    Jinsoo Chung
    [J]. BMC Cancer, 16
  • [35] A moncentric review of targeted therapy on overall survival in metastatic renal clear cell carcinoma
    Tadj, Melanie
    Arnoux, Valentin
    Mousseau, Mireille
    Descotes, Jean Luc
    Quesada, Jean-Louis
    Bensaadi, Lamia
    Laramas, Mathieu
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [36] Progression-free survival (PFS) and overall survival (OS) across ethnicities for patients with metastatic renal cell carcinoma (mRCC) receiving targeted therapies (TT) as first-line (1L) treatment
    Salgia, Nicholas
    Dizman, Nazli
    Bergerot, Paulo Gustavo
    Bergerot, Cristiane Decat
    Hsu, Joann
    Pal, Sumanta K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [37] Real-World Effectiveness of Everolimus Subsequent to Different First Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Synthesis of Retrospective Chart Reviews
    Pal, Sumanta K.
    Signorovitch, James E.
    Reichmann, William M.
    Li, Nanxin
    Koo, Valerie
    Liu, Zhimei
    Perez, Jose Ricardo
    Vogelzang, Nicholas J.
    [J]. CLINICAL GENITOURINARY CANCER, 2016, 14 (02) : 160 - +
  • [38] Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma: a systematic review and meta-analysis
    Goudarzi, Zahra
    Mostafavi, Mehrdad
    Salesi, Mahmood
    Jafari, Mojtaba
    Mirian, Iman
    Hashemi Meshkini, Amir
    Keshavarz, Khosro
    Ghasemi, Younes
    [J]. COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2023, 21 (01)
  • [39] Comparative effectiveness of everolimus (EVE) and axitinib (AXI) for 2nd targeted therapy (TT) of metastatic renal cell carcinoma (mRCC) in the US: A retrospective chart review
    Signorovitch, James E.
    Pal, Sumanta Kumar
    Reichmann, William M.
    Li, Nanxin
    Liu, Zhimei
    Perez, Jose Ricardo
    Vogelzang, Nicholas J.
    Jonasch, Eric
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [40] Progression-free survival (PFS) of first-line VEGF-targeted therapy as a prognostic parameter for overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).
    Seidel, C.
    Fenner, M.
    Reuter, C. W.
    Ganser, A.
    Gruenwald, V.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345